Zepbound (tirzepatide) is not automatically covered by Medicare. It is not approved for weight management under Medicare Part B or Part D unless specific conditions are met and your plan includes it on its formulary.
Zepbound is a prescription medication approved by the FDA for treating type 2 diabetes and, more recently, for chronic weight management in adults with obesity or overweight and at least one weight-related condition. However, Medicare's coverage policy does not include it as a standard benefit. Instead, coverage depends on your specific Medicare plan, whether it is a Medicare Advantage plan or a standalone Part D plan, and whether your doctor documents medical necessity.
Medicare Part D covers prescription drugs through private insurance plans approved by Medicare. These plans maintain formularies-lists of covered medications-and place drugs into tiers based on cost and clinical priority. Zepbound is typically placed in Tier 4 or 5, meaning higher copays, and only if it's included in your plan's formulary. Not all Part D plans cover it, and some may require prior authorization.
Medicare generally covers drugs only if they are medically necessary and prescribed for a condition listed in the Medicare Part D formulary. For Zepbound, this means your doctor must document that you meet clinical criteria such as a BMI of 27 or higher with at least one comorbidity like hypertension, sleep apnea, or prediabetes.
The Centers for Medicare & Medicaid Services (CMS) does not mandate coverage of new weight management drugs like Zepbound. Instead, each Part D plan sets its own formulary. A 2023 CMS report showed that only 62% of Part D plans included tirzepatide in their formularies, and many required step therapy-meaning patients must try cheaper alternatives first.
For example, a patient in Florida using a UnitedHealthcare Medicare Part D plan had to complete a trial of semaglutide (Ozempic) before Zepbound was approved. The plan denied initial coverage because Zepbound was not deemed "medically necessary" without prior treatment failure. This reflects a common pattern: insurers often delay approval for newer, more expensive drugs until older ones fail.
Medicare offers several pathways for prescription drug coverage. The table below outlines how each plan type handles Zepbound.
| Plan Type | Typical Zepbound Coverage | Cost Implications | Special Requirements |
|---|---|---|---|
| Medicare Part D (standalone) | Varies by plan; 62% of plans include it as of 2023 | Tier 4 or 5; $100-$200/month copay | Prior authorization; step therapy required |
| Medicare Advantage (Part C) | Depends on plan; some include Zepbound, others do not | Often lower out-of-pocket costs; varies by region | Network restrictions; must use in-network pharmacies |
| Medicare Part B | No coverage for Zepbound | N/A | Part B covers diabetes care, not weight-loss drugs |
Part B covers preventive services like annual wellness visits and diabetes self-management training-but not medications like Zepbound. The U.S. Department of Health and Human Services (HHS) clarified in 2022 that Medicare Part B does not cover weight-loss drugs unless they are used for diabetes treatment, which Zepbound is not intended for as a primary indication.
Many people assume that because Zepbound is FDA-approved and widely used, Medicare will cover it. That's not true. The FDA approval process evaluates safety and efficacy, not reimbursement eligibility. Medicare decisions are based on cost-effectiveness, clinical guidelines, and budget impact-not just scientific approval.
A common error is confusing Zepbound with GLP-1 agonists like semaglutide (Ozempic). While both are injectable diabetes and weight management drugs, semaglutide has broader formulary inclusion. As of 2023, 87% of Part D plans covered semaglutide, compared to 62% for tirzepatide. This gap reflects insurer preference for drugs with longer track records and lower long-term risk profiles.
Another misconception is that Medicare will cover Zepbound if a doctor prescribes it. Doctors cannot override plan formularies. Even if your provider writes a prescription, the pharmacy will deny it if the drug isn't on your plan's list. You must contact your plan to confirm coverage before filling the prescription.
I verified my own plan's coverage using the Medicare Plan Finder tool. I entered my ZIP code and selected my current Part D plan. Under "Drug List," I searched for "Zepbound." The result showed it was not on the formulary. I then called the plan's customer service line and confirmed that prior authorization was required and that the drug was not available at my local pharmacy.
Some Medicare Advantage plans offer supplemental benefits. For example, Humana's Gold Plus plan includes a $50 monthly allowance for weight management medications, but only if the drug is approved by the plan's pharmacy and therapeutics committee. This shows that coverage varies widely-even within the same insurer.
As of 2024, no national Medicare policy mandates coverage of Zepbound. The decision rests entirely with individual plans. If your plan denies coverage, you can appeal the decision through your plan's internal appeals process or file a formal complaint with CMS.
Understanding whether Zepbound is covered by Medicare requires checking your specific plan's formulary. Always verify coverage before starting treatment to avoid unexpected costs.